A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.

Trial Profile

A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type IIb
  • Focus Therapeutic Use
  • Sponsors Genfit
  • Most Recent Events

    • 03 Jul 2012 Trial location (France) identified, planned patient number 30 added as reported by EudarCT.
    • 03 Jul 2012 Official title amended as reported by EudraCT.
    • 09 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top